10-Q: Coherus Oncology Boosts Cash, Focuses on Immuno-Oncology

Coherus Oncology, Inc. reported a significant net income driven by the divestiture of its biosimilar businesses, while continuing to advance its immuno-oncology pipeline and commercialize LOQTORZI.

Summary

• The company completed the divestiture of its UDENYCA business on April 11, 2025, for upfront cash consideration of $483.4 million, inclusive of $118.4 million for product inventory, resulting in a net gain of $339.1 million.
• Substantially all outstanding 2026 Convertible Notes were repaid, including $170.0 million on April 15, 2025, and $59.9 million on May 15, 2025, and UDENYCA royalty rights were bought out for $47.7 million.
• Net income for the three months ended June 30, 2025, was $297.8 million, a significant improvement from a net loss of $12.9 million in the same period last year, primarily due to the UDENYCA divestiture gain.
• Net income for the six months ended June 30, 2025, was $241.2 million, up from $89.9 million in the prior year period.
• LOQTORZI net revenue increased to $9.96 million for Q2 2025 from $3.79 million for Q2 2024, and to $17.31 million for 6M 2025 from $5.78 million for 6M 2024, driven by volume growth.
• Cash, cash equivalents, and marketable securities increased to $237.6 million as of June 30, 2025, from $126.0 million at December 31, 2024.
• Research and development expenses from continuing operations increased to $26.31 million for Q2 2025 from $20.60 million for Q2 2024, primarily due to increased development costs for casdozokitug and CHS-114.
• Selling, general and administrative expenses from continuing operations decreased to $26.04 million for Q2 2025 from $27.52 million for Q2 2024, mainly due to lower average headcount.
• Gross margin from continuing operations decreased to 67% for Q2 2025 from 82% for Q2 2024, and to 66% for 6M 2025 from 74% for 6M 2024.

Sentiment

Score: 8

Explanation: The company's strategic pivot to immuno-oncology is well-funded by successful biosimilar divestitures, significantly improving its financial position and reducing debt. Strong LOQTORZI revenue growth and its favorable NCCN guideline status are key positives. While R&D expenses are increasing for pipeline development and a Nasdaq listing issue exists, the overall financial health and strategic clarity are strong.

Positives

• Successful divestiture of biosimilar businesses, including UDENYCA for $483.4 million, significantly improving the cash position and reducing liabilities.
• Substantial increase in net income for both the quarter ($297.8 million) and six-month period ($241.2 million) due to divestiture gains.
• Strong volume growth for LOQTORZI, with net revenue increasing by $6.17 million in Q2 2025 and $11.53 million in 6M 2025 compared to prior year periods.
• LOQTORZI is now the only preferred Category 1 first-line treatment option for metastatic or recurrent locally advanced NPC in NCCN guidelines, enhancing its market position.
• Significant reduction in total liabilities from $580.5 million to $319.6 million, primarily due to debt repayment from divestiture proceeds.
• Cash, cash equivalents, and marketable securities increased by over $111 million since year-end 2024, providing stronger liquidity for future operations and pipeline development.

Negatives

• Gross margin from continuing operations decreased significantly from 82% to 67% in Q2 2025 and from 74% to 66% in 6M 2025.
• Operating loss from continuing operations increased to $(45.49) million in Q2 2025 from $(39.63) million in Q2 2024.
• The company is highly dependent on LOQTORZI and its unapproved pipeline candidates for future revenue, with inherent risks in drug development.
• Uncertainty regarding the receipt of two $37.5 million earnout payments from the UDENYCA sale, which are contingent on future net sales thresholds.
• Received a Nasdaq listing compliance notice due to the common stock bid price falling below $1.00, with a deadline of December 29, 2025, to regain compliance.
• Identified a material weakness in internal control over financial reporting related to documentation and review of certain inventory account reconciliations, though it did not result in a misstatement.

Risks

• Ability to maintain or increase sales for LOQTORZI and successfully develop and commercialize product candidates.
• Reliance on third-party contract manufacturers and contract research organizations (CROs), with potential risks of supply disruptions, quality issues, and regulatory non-compliance.
• Intense competition from other immuno-oncology biologics, including established products and new market entrants.
• Uncertainty of third-party payer coverage and adequate reimbursement for LOQTORZI and future products.
• Potential adverse impact of healthcare reform measures, including the Inflation Reduction Act of 2022 and the One Big Beautiful Bill Act, on pricing and profitability.
• Dependence on key executives and personnel, with risks related to retention and recruitment.
• Risks associated with international business, including conflicting laws, regulatory approvals, and geopolitical tensions (e.g., war in Ukraine, Middle East conflicts).
• Potential for undesirable side effects or other properties of products/candidates to delay or prevent regulatory approval, limit commercial profile, or result in negative consequences post-marketing.
• Risk of infringing intellectual property rights of third parties, which could lead to litigation, substantial costs, or inability to commercialize products.
• Uncertainty of obtaining and maintaining effective patent rights, and risks from 'submarine patents' (patents issuing from previously unpublished applications).
• Risks related to the UDENYCA Transition Services Agreement (TSA), including diversion of management time and unanticipated costs.
• Exposure to adverse developments in the financial services industry affecting cash and liquidity.
• Volatility of common stock price and potential for substantial losses for purchasers.
• Risk of delisting from the Nasdaq Global Market if listing compliance requirements are not met.
• Potential for future capital raises to dilute existing stockholders.
• Legal proceedings and claims, such as the $14.0 million demand from Zinc Health Services, LLC, with uncertain final resolution.
• Impact of continued inflation on costs and margins.
• Environmental, health, and safety law compliance risks.

Future Outlook

Net revenue from continuing operations in 2025 is expected to be higher than in 2024 due to continued growth of LOQTORZI. Research and development expenses are anticipated to be higher in 2025 than 2024 due to continued investments in the immuno-oncology pipeline. Selling, general and administrative expenses for the full year 2025 are expected to be lower than 2024 due to decreased operating costs and headcount from divestitures. Interest expense from continuing operations is expected to be lower in 2025 than 2024 due to debt repayment. The company believes its available cash, cash equivalents, marketable securities, product sales, and ATM Offering proceeds will be sufficient to fund planned expenditures and meet obligations for at least the next twelve months, but may need to raise additional funds sooner than expected.

Management Comments

• Our strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both our pipeline candidates as well as our industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents.
• We expect net revenue from continuing operations in 2025 to be higher than in 2024 because of continued growth of LOQTORZI.
• We expect our research and development expense in 2025 to be higher than 2024 due to continued investments in our immuno-oncology pipeline.
• We expect our selling, general and administrative expense from continuing operations for the full year 2025 to be lower than the full year 2024 primarily as a result of decreased operating costs and headcount due to divestitures.
• We believe that our available cash, cash equivalents and marketable securities, product sales, and ATM Offering proceeds received to date will be sufficient to fund our planned expenditures and meet our obligations for at least the twelve months following our financial statement issuance date.

Industry Context

Coherus Oncology, Inc. is undergoing a significant strategic transformation, divesting its biosimilar businesses to exclusively focus on innovative immuno-oncology. This aligns with a broader industry trend where companies specialize to maximize value from high-potential, novel therapies. The company's lead product, LOQTORZI, is positioned in the competitive PD-1 inhibitor market, but its recent inclusion as the only preferred Category 1 first-line treatment for nasopharyngeal carcinoma (NPC) in NCCN guidelines provides a strong competitive advantage in this niche. The pipeline candidates, Casdozokitug (IL-27 targeting) and CHS-114 (CCR8 targeting), represent efforts to explore new mechanisms in immuno-oncology, a high-growth area. The divestiture of mature biosimilar assets for substantial cash allows the company to de-lever and reinvest in its oncology pipeline, a common strategy for biotech firms seeking to fund R&D without excessive dilution.

Comparison to Industry Standards

• The company's strategic shift to focus solely on immuno-oncology is comparable to other biotech firms that streamline their portfolios to concentrate on high-value, innovative drug development, such as when Amgen divested its biosimilar assets to focus on novel therapies.
• LOQTORZI's designation as the only preferred Category 1 first-line treatment for NPC in NCCN guidelines is a significant competitive differentiator, similar to how Keytruda (pembrolizumab) from Merck has achieved dominant positions in certain indications due to strong clinical data and guideline inclusion.
• The gross margin decline from 82% to 67% (Q2 2025 vs Q2 2024) for continuing operations suggests a shift in product mix or pricing pressures specific to the oncology segment, which can have different cost structures (e.g., higher royalty payments) compared to biosimilars.
• The company's cash position of $237.6 million after significant divestitures and debt repayment provides a stronger financial runway compared to many early-stage biotech companies that frequently rely on dilutive financing.
• The Nasdaq minimum bid price deficiency is a common challenge for smaller biotech companies, and the company's plan to monitor and potentially execute a reverse stock split is a standard response, similar to actions taken by companies like Sorrento Therapeutics or Aeterna Zentaris in the past.

Management Changes

Corporate Governance

Legal Proceedings

• A demand letter was received from Zinc Health Services, LLC asserting a claim for approximately $14.0 million related to certain sales of UDENYCA from October 2020 through December 2021. The company has an accrual of $6.4 million as of June 30, 2025, and the final resolution is uncertain.

Stakeholder Impact

• Shareholders: Potential for increased value due to strategic focus on oncology and improved financial health from divestitures. Risk of dilution from future capital raises (ATM Offering) and potential delisting from Nasdaq if bid price compliance is not met.
• Employees: Reduced headcount due to divestitures, but continued equity incentives (ESPP, Equity Incentive Plan) aim to retain talent in the new oncology-focused structure.
• Customers/Patients: Continued supply and commercialization of LOQTORZI for NPC patients. Potential for new treatment options if pipeline candidates (Casdozokitug, CHS-114) gain approval.
• Creditors: Improved financial position and reduced debt obligations enhance the company's ability to meet its financial commitments.
• Suppliers/Partners: Continued reliance on third-party manufacturers and CROs, with ongoing purchase commitments.

Next Steps

• Expand the use of LOQTORZI in nasopharyngeal carcinoma (NPC).
• Advance the development of new indications for LOQTORZI in combination with pipeline candidates and industry partners.
• Continue clinical studies for Casdozokitug (CHS-388) in advanced solid tumors and HCC.
• Continue clinical studies for CHS-114 in second-line HNSCC and advanced solid tumors (gastric, esophageal squamous cell cancer).
• Monitor and evaluate options to regain compliance with Nasdaq minimum bid price requirement by December 29, 2025.
• Evaluate the impacts of the One Big Beautiful Bill Act (OBBBA) on financial statements, with effects beginning to be reflected in Q3 2025.
• Evaluate the impact of ASU 2023-09 (Income Taxes) on financial statement disclosures, effective for annual periods beginning after December 15, 2024.
• Evaluate the impact of ASU 2024-03 (Income Statement Expense Disaggregation) on financial statement disclosures, effective for annual periods beginning after December 15, 2026.
• Address the material weakness in internal control over financial reporting related to inventory account reconciliations, though the specific control was decommissioned.
• Potentially receive two $37.5 million earnout payments from the UDENYCA sale, contingent on future net sales thresholds.

Key Dates

Recommendation

The company has made a significant strategic pivot by divesting its biosimilar assets, which has substantially improved its cash position and reduced debt. The focus on immuno-oncology, particularly with LOQTORZI's strong market positioning in NPC, presents a clear growth path. However, the company still faces an operating loss from continuing operations, a declining gross margin, and the inherent risks of drug development for its pipeline candidates. The Nasdaq listing compliance issue adds a layer of uncertainty. While the long-term strategic direction is positive, the immediate financial performance from continuing operations and the Nasdaq compliance issue suggest a 'hold' position until there is clearer evidence of sustained profitability from the oncology segment and resolution of the listing concern.

Keywords

Coherus Oncology, Immuno-oncology, LOQTORZI, Cancer Treatment, PD-1 Inhibitor, Nasopharyngeal Carcinoma, Biotechnology, Pharmaceuticals, Biosimilars Divestiture, Financial Results, SEC Filing, Nasdaq Listing, Clinical Trials, Drug Development, Risk Factors